or both – as well as ApoE4 status and geographical region. Clarity AD’s phase 3 primary endpoint was change from baseline at 18 months in the CDR-SB (Clinical Dementi Rating Sum of Boxes), the ...

I-PREDICT matched McKeown with nivolumab, a checkpoint inhibitor approved for advanced ... problems I can’t do anything about, such as the APOE4 gene, which elevates the risk of Alzheimer ...

Oct. 22, 2024 — Adults with type 2 diabetes on a low-carbohydrate diet may see benefits to their beta-cell function allowing them to better manage their disease and ... Oct. 17, 2024 ...

In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade. However, expanded ...

The current human tissue-based study provides convincing evidence correlating hippocampal expressions of RNA guanine-rich G-quadruplexes with aging and with Alzheimer's Disease presence and severity.